AR111474A1 - Compuestos químicos - Google Patents

Compuestos químicos

Info

Publication number
AR111474A1
AR111474A1 ARP180100956A ARP180100956A AR111474A1 AR 111474 A1 AR111474 A1 AR 111474A1 AR P180100956 A ARP180100956 A AR P180100956A AR P180100956 A ARP180100956 A AR P180100956A AR 111474 A1 AR111474 A1 AR 111474A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
independently selected
heterocyclyl
oxygen
Prior art date
Application number
ARP180100956A
Other languages
English (en)
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR111474A1 publication Critical patent/AR111474A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente solicitud se refiere a compuestos y sales de los mismos, como inhibidores de la actividad de cinasa, en particular, la actividad de PI3-cinasa. Reivindicación 1: Un compuesto de fórmula (1), en la que R¹ es heteroarilo de 5 ó 6 miembros, en el que dicho heteroarilo contiene de uno a tres heteroátomos seleccionados independientemente entre oxígeno y nitrógeno y está sustituido con uno o dos sustituyentes seleccionados independientemente entre halo, ciano, alcoxi C₁₋₆, -NHSO₂-alquilo C₁₋₆, -XR³ y alquilo C₁₋₆ en donde el alquilo C₁₋₆ está opcionalmente sustituido con halo; R² es -OR⁴, -CONHR⁵ o heteroarilo de 5 ó 6 miembros en el que el heteroarilo contiene de uno a tres heteroátomos seleccionados independientemente entre oxígeno y nitrógeno y está sustituido con uno o dos sustituyentes seleccionados independientemente entre halo, ciano, alcoxi C₁₋₆, -NHSO₂-alquilo C₁₋₆, -CONR⁶R⁷, -YR⁸ y alquilo C₁₋₆ en donde el alquilo C₁₋₆ esta opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente entre hidroxi y -NR⁹R¹⁰; R³ es heterociclilo de 5 ó 6 miembros en el que el heterociclilo contiene uno o dos heteroátomos seleccionados independientemente entre oxígeno y nitrógeno y está opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre alquilo C₁₋₆; R⁴ es alquilo C₁₋₆ opcionalmente sustituido con cicloalquilo C₃₋₆ o heterociclilo de 5 ó 6 miembros que contiene uno o dos heteroátomos seleccionados entre oxígeno y nitrógeno en donde el cicloalquilo C₃₋₆ está opcionalmente sustituido con -NHCO₂-alquilo C₁₋₆ y el heterociclilo está opcionalmente sustituido con de uno a tres sustituyentes seleccionados independientemente entre halo, -CO-alquilo C₁₋₆, -CO₂-alquilo C₁₋₆ y alquilo C₁₋₆ opcionalmente sustituido con -OR¹¹; R⁵ es hidrógeno o alquilo C₁₋₆ opcionalmente sustituido con heterociclilo de 6 miembros en el que el heterociclilo contiene un átomo de oxígeno o un átomo de nitrógeno y está opcionalmente sustituido con alquilo C₁₋₆; R⁶ y R⁷, junto con el átomo de nitrógeno al que están unidos, está unidos para formar un heterociclilo de 5 ó 6 miembros en donde el heterociclilo opcionalmente contiene un átomo de oxígeno o un átomo de nitrógeno adicional y está opcionalmente sustituido con alquilo C₁₋₆; R⁸ es un heterociclilo de 5 a 9 miembros en el que el heterociclilo contiene uno o dos heteroátomos seleccionados independientemente entre oxígeno y nitrógeno y está sustituido con uno a tres sustituyentes seleccionados independientemente entre oxo, hidroxi, halo, -CO-alquilo C₁₋₆ y alquilo C₁₋₆ opcionalmente sustituido con -OR¹²; cada uno de R⁹, R¹⁰, R¹¹ y R¹² es independientemente hidrógeno o alquilo C₁₋₆; cada uno de X e Y es independientemente -CH₂- o -CH(CH₃)-; o una sal del mismo. Reivindicación 7: Un compuesto que es de fórmula (2), o una sal del mismo.
ARP180100956A 2017-04-18 2018-04-16 Compuestos químicos AR111474A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1706102.9A GB201706102D0 (en) 2017-04-18 2017-04-18 Chemical compounds

Publications (1)

Publication Number Publication Date
AR111474A1 true AR111474A1 (es) 2019-07-17

Family

ID=58744410

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100956A AR111474A1 (es) 2017-04-18 2018-04-16 Compuestos químicos

Country Status (12)

Country Link
US (1) US11555040B2 (es)
EP (1) EP3612536B1 (es)
JP (1) JP7080900B2 (es)
CN (1) CN110785420B (es)
AR (1) AR111474A1 (es)
BR (1) BR112019021709A2 (es)
CA (1) CA3058969A1 (es)
ES (1) ES2906956T3 (es)
GB (1) GB201706102D0 (es)
TW (1) TW201902899A (es)
UY (1) UY37681A (es)
WO (1) WO2018192864A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021035911A (ja) * 2017-11-15 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体及びその医薬用途
JP7242548B2 (ja) 2017-11-24 2023-03-20 住友ファーマ株式会社 ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
CA2361954C (en) 1995-04-14 2003-07-08 Smithkline Beecham Corporation Metered dose inhaler for albuterol
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6255303B1 (en) 1998-03-14 2001-07-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone PDE III/IV inhibitors
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
CA2371273A1 (en) 1999-05-04 2000-11-09 Andrew Fensome Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
EP1305329B2 (en) 2000-08-05 2015-03-18 Glaxo Group Limited 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-furanylcarboxyl)oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
BR0209271A (pt) 2001-04-30 2004-06-15 Glaxo Group Ltd Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
US20040248867A1 (en) 2001-06-12 2004-12-09 Keith Biggadike Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
SI1425001T1 (sl) 2001-09-14 2009-04-30 Glaxo Group Ltd Glaxo Welcome Fenetanolaminski derivati za zdravljenje respiratornih bolezni
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
CA2472746A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
AU2003214879B2 (en) 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
ES2298508T3 (es) 2002-03-26 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos.
CA2477764A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
DE60335869D1 (de) 2002-04-11 2011-03-10 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
EP1497261B1 (en) 2002-04-25 2007-12-19 Glaxo Group Limited Phenethanolamine derivatives
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PT1521733E (pt) 2002-07-08 2014-10-29 Pfizer Prod Inc Moduladores do recetor de glucocorticoides
WO2004009017A2 (en) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
PL375993A1 (en) 2002-09-16 2005-12-12 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
AU2003270783C1 (en) 2002-09-20 2010-05-20 Merck Sharp & Dohme Corp. Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2003298094A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Medicinal arylethanolamine compounds
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
ATE390407T1 (de) 2002-10-28 2008-04-15 Glaxo Group Ltd Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
NZ556424A (en) 2003-10-14 2008-12-24 Glaxo Group Ltd Muscarinic Acetylcholine receptor antagonists
EP1699512B1 (en) 2003-11-03 2012-06-20 Glaxo Group Limited A fluid dispensing device
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
US20070111995A1 (en) 2003-12-19 2007-05-17 Allen David G Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
EP1735314A1 (en) 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
MX2007004465A (es) 2004-10-19 2007-05-07 Hoffmann La Roche Derivados de quinolina.
US20090124588A1 (en) 2005-01-10 2009-05-14 Glaxo Group Limited Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
NZ556686A (en) 2005-02-14 2010-01-29 Bionomics Ltd Novel tubulin polymerisation inhibitors
RS52195B (en) * 2005-09-23 2012-10-31 Janssen Pharmaceutica N.V. MODULATOR HEXA HYDROCYCLOHEPTAPIRAZOLE Cannabinoids
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
EP2350084B1 (en) * 2008-10-17 2015-06-24 Boehringer Ingelheim International GmbH Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
CN104781238A (zh) * 2012-08-10 2015-07-15 弗·哈夫曼-拉罗切有限公司 吡唑甲酰胺化合物、组合物及使用方法
AR098776A1 (es) * 2013-12-18 2016-06-15 Chiesi Farm Spa Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
CA2988601C (en) * 2015-07-02 2021-12-07 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
JP2021035911A (ja) * 2017-11-15 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体及びその医薬用途

Also Published As

Publication number Publication date
GB201706102D0 (en) 2017-05-31
ES2906956T3 (es) 2022-04-21
EP3612536A1 (en) 2020-02-26
CA3058969A1 (en) 2018-10-25
TW201902899A (zh) 2019-01-16
US20220324875A1 (en) 2022-10-13
BR112019021709A2 (pt) 2020-05-12
WO2018192864A1 (en) 2018-10-25
EP3612536B1 (en) 2021-12-15
CN110785420A (zh) 2020-02-11
JP2020517610A (ja) 2020-06-18
CN110785420B (zh) 2022-04-26
US11555040B2 (en) 2023-01-17
JP7080900B2 (ja) 2022-06-06
UY37681A (es) 2018-11-30

Similar Documents

Publication Publication Date Title
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR110922A1 (es) Compuestos inhibidores del vih
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR103561A1 (es) Fenilpiridinas herbicidas
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR101600A1 (es) COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53
AR095508A1 (es) 4-amino-6-(heterocíclico)picolinatos y 6-amino-2-(heterocíclico)pirimidina-4-carboxilatos y su uso como herbicidas
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR096613A1 (es) Moduladores de la acetil-coa carboxilasa
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR097755A1 (es) Derivados sustituidos de fenilalanina como moduladores del factor xia
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR111248A1 (es) Derivados de ciclopropilmetilamida activos como pesticida
AR101489A1 (es) Compuestos reguladores del crecimiento vegetal
AR111474A1 (es) Compuestos químicos
AR096984A1 (es) Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona
AR096827A1 (es) Uso de piridoncarboxamidas seleccionadas o sus sales como ingredientes activos contra estrés abiótico en plantas
AR096614A1 (es) Moduladores de la acetil-coa carboxilasa
AR107570A1 (es) Compuestos químicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure